STOCK TITAN
  1. Home
  2. News
  3. CDXC

Chromadex Corp - CDXC STOCK NEWS

IMPACT
SENTIMENT
CDXC : Nasdaq
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
clinical trial
IMPACT
SENTIMENT
CDXC : Nasdaq
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
clinical trial
IMPACT
SENTIMENT
CDXC : Nasdaq
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023
conferences
IMPACT
SENTIMENT
CDXC : Nasdaq
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
earnings
IMPACT
SENTIMENT
CDXC : Nasdaq
ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide
IMPACT
SENTIMENT
CDXC : Nasdaq
ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
conferences earnings
IMPACT
SENTIMENT
CDXC : Nasdaq
ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line
IMPACT
SENTIMENT
CDXC : Nasdaq
A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients
clinical trial
IMPACT
SENTIMENT
CDXC : Nasdaq
Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN
clinical trial
IMPACT
SENTIMENT
CDXC : Nasdaq
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
earnings
Stock CDXC logo
Chromadex Corp

Nasdaq:CDXC

CDXC Rankings

#5109 Ranked by Market Cap
#2909 Ranked by Stock Gains
N/A Ranked by Dividends

CDXC Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Los Angeles

About CDXC

chromadex corp. is an integrated, global nutraceutical company devoted to improving the way people age. chromadex scientists partner with leading universities and research institutions worldwide to uncover the full potential of nad and identify and develop novel, science-based ingredients including pteropure® pterostilbene; purenergy®, a caffeine-pteropure® co-crystal; anthorigin™, anthocyanins and niagen® nicotinamide riboside - sold directly to consumers as the supplement, tru niagen®. tru niagen® is helping the world age better®. for more, visit www.chromadex.com like us on facebook here: https://www.facebook.com/chromadex or follow us on twitter @chromadex chromadex® is publicly-traded company (nasdaq:cdxc).